Bioscience Pharma is singularly focused on Neuroinflammation and Neurodegenerative Diseases.
Organized in 2014 to advance results of our early studies into the effects of leukotriene pathway inhibitors on the initiation and progression of neuroinflammation. Our patented lead therapeutic is BPP-1001.
Our studies have added importantly to the growing knowledge of neuroinflammation as the initial mechanism of action leading to onset and progression of most Central Nervous System (CNS) disorders, including Traumatic head injury, Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, COVID, Viral encephalitis, and Aging.